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The US11 gene product of human cytomegalovirus promotes viral
immune evasion by hijacking the endoplasmic reticulum (ER)-asso-
ciated degradation (ERAD) pathway. US11 initiates dislocation of
newly translocated MHC I from the ER to the cytosol for protea-
some-mediated degradation. Despite the critical role for ubiquitin
in this degradation pathway, the responsible E3 ligase is unknown.
In a forward genetic screen for host ERAD components hijacked
by US11 in near-haploid KBM7 cells, we identified TMEM129, an
uncharacterized polytopic membrane protein. TMEM129 is essen-
tial and rate-limiting for US11-mediated MHC-I degradation and
acts as a novel ER resident E3 ubiquitin ligase. TMEM129 contains
an unusual cysteine-only RING with intrinsic E3 ligase activity and
is recruited to US11 via Derlin-1. Together with its E2 conjugase
Ube2J2, TMEM129 is responsible for the ubiquitination, disloca-
tion, and subsequent degradation of US11-associated MHC-I. US11
engages two degradation pathways: a Derlin-1/TMEM129–depen-
dent pathway required for MHC-I degradation and a SEL1L/HRD1-
dependent pathway required for “free” US11 degradation. Our data
show that TMEM129 is a novel ERAD E3 ligase and the central com-
ponent of a novel mammalian ERAD complex.
Proteins inserted into the endoplasmic reticulum (ER) mustfold and acquire their native state before further trafficking
through the secretory pathway (1, 2). To avoid the toxicity as-
sociated with misfolded gene products, all proteins must pass the
ER quality-control checkpoint. Misfolded proteins are rejected
and dislocated across the ER-membrane for cytosolic protea-
some degradation in a process known as ER-associated degra-
dation (ERAD). ERAD degrades misfolded and unassembled
proteins and regulates turnover of ER-resident proteins (3).
Ubiquitination of the protein substrate provides a critical step
in protein dislocation (4). The RING family constitutes the largest
family of E3 ligases, including those involved in ERAD (5). The
RING domain creates a binding platform for the E2 conjugase
and consists of two zinc atoms coordinated in a cross-brace motif
via interspersed cysteine (C) and histidine (H) residues in a
C3HC4, C3H2C3, or C4HC3 conformation (5). Most ERAD E3
ligases are integral membrane proteins; they form the core of the
ERAD machinery, nucleating functionally distinct ERAD com-
plexes. The mammalian system is more complex than yeast and
has undergone an expansion of the ERAD E3 ligase family, with
the Hrd1p homologs Hrd1 and Gp78, the Doa10p homolog
MARCH6, RNF5, TRC8, and CHIP (3, 4).
Many pathogens appropriate the ubiquitin-proteasome sys-
tem, particularly to degrade components of the host immune
system (6, 7). The human cytomegalovirus (HCMV) US2 and
US11 gene products have been instrumental in studies of the
mammalian ERAD system. These viral proteins hijack separate
components of the ERAD system to degrade MHC-I, thus pre-
venting cytotoxic T lymphocyte recognition of infected cells (8, 9).
US2 appropriates the TRC8 E3 ubiquitin ligase (10), whereas
dislocation induced by US11 is reported to be dependent on
components of the canonical “HRD1 retrotranslocation machin-
ery,” including the rhomboid pseudoprotease Derlin-1 (11, 12),
SEL1L (13), AUP1, and UBXD8 (14). Despite recruiting these
components HRD1 is not itself required for US11-mediated
degradation, and the ERAD E3 ligase central to US11-mediated
degradation remains undefined.
To further understand how US11 works, we used a forward
genetic screen in US11-expressing KBM7 cells which are haploid
for all chromosomes except chromosome 8, allowing gene dis-
ruption by targeting of a single gene copy (15, 16). We identified
TMEM129, an uncharacterized membrane protein, as essential and
rate-limiting for US11-mediated MHC-1 degradation. TMEM129
contains a novel and atypical RING domain with intrinsic protein
E3 ubiquitin ligase activity. The loss of TMEM129 abolishes MHC-I
ubiquitination in the presence of US11 and prevents MHC-I ret-
rotranslocation and proteasomal degradation. TMEM129 is there-
fore a novel ERAD E3 ligase hijacked by HCMVUS11 and critical
for HCMV immune modulation.
Results
A Haploid Genetic Screen Identifies TMEM129 as an Essential Cellular
Gene in the US11-Mediated Down-Regulation of MHC Class I Molecules.
To identify novel host factors required for the US11-mediated
degradation of MHC-I molecules, we screened near-haploid KBM7
cells. Our rationale was that disruption of a gene essential for US11
activity would rescue MHC-I from degradation and increase cell
surface MHC-I (Fig. 1A). We screened on a KBM7 US11 internal
ribosome entry site (IRES) CFP clone with low cell-surface en-
dogenous HLA-A2 (Fig. 1B) and also selected for CFP as a sur-
rogate marker of US11. After retroviral mutagenesis of US11
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KBM7 cells, we enriched for rare HLA-A2high, CFP+ cells by it-
erative FACS (Fig. 1B). Following the second sort, a population
of >90% HLA-A2high CFP+ cells was identified. Retroviral in-
tegration sites, mapped by splinkerette-PCR and 454 pyrose-
quencing, revealed 40 independent retroviral insertions in the
uncharacterized TMEM129 gene on chromosome 4 (Fig. 1C). No
other clusters of retroviral insertion sites were found; TMEM129
therefore represents the only bona fide hit from the screen.
To verify the requirement for TMEM129 in US11-mediated
degradation, we isolated a US11+, TMEM129 gene-trap clone
(TMEM129GT) and confirmed the absence of TMEM129 mRNA
(Fig. 2A, Upper), and protein (Fig. 2A, Lower) with a TMEM129-
specific antibody that detects a 36-kDa band, absent from
TMEM129GT cells (Fig. 2A, Lower). Immunoblot analysis of US11+
TMEM129GT cells showed a full restoration of MHC-I (Fig. 2B),
although only a partial cell surface rescue of HLA-A2 (Fig. 2C,
first panel, red line). Exogenous HA-tagged TMEM129 in US11
TMEM129GT cells restored US11 activity with a complete loss of
cell surface HLA-A2 (Fig. 2C, second panel, red line), proving an
absolute requirement for TMEM129 for US11 function. US11
targets the endogenous HLA-B allele of KBM7 (HLA-B60) less
effectively than HLA-A2, causing only a partial cell surface loss of
HLA-B (Fig. 2C, third panel, green line), which is also depen-
dent on TMEM129 (Fig. 2C, third panel, red line). Exogenous
TMEM129-HA induced further down-regulation of cell surface
HLA-B (Fig. 2C, fourth panel, red line) beyond that seen in the
original US11 cell (Fig. 2C, fourth panel, red line), suggesting
TMEM129 is both essential and rate-limiting for US11-mediated
MHC-I degradation. This finding was confirmed by showing that
TMEM129 overexpression in KBM7 US11 cells further down-
regulated HLA-B (Fig. S1A). This requirement for TMEM129
on US11 activity was not limited to KBM7 cells. siRNA TMEM129
depletion rescued GFP–HLA-A2 expression in HeLa-US11 GFP–
HLA-A2 cells (Fig. S1B), suggesting a general requirement for
TMEM129 in US11 activity. The specificity of TMEM129 for the
US11 dislocation pathway was confirmed, as TMEM129 de-
pletion did not rescue GFP–HLA-A2 in US2-expressing HeLa
cells (Fig. S1C).
We wanted to ascertain whether TMEM129 is also required
for the down-regulation of MHC-I in HCMV-infected cells. We
therefore depleted TMEM129 from fibroblasts that were then
infected with the HCMV TB40Bac4 strain, which lacks the
IRS1-US9 genes and is reliant on US11 for MHC-I down-
regulation. Depletion of TMEM129 prevented the loss of HLA-
A2 in HCMV infection (Fig. 2D) and also increased US11 ex-
pression. TMEM129 is therefore responsible for the US11-induced
down-regulation of MHC-I in HCMV infection.
TMEM129 depletion rescued endogenous MHC-1 (Fig. 2B),
but failed to completely restore cell surface HLA-A2 expression
(Fig. 2C), implying MHC-I must be retained within the cell. We
therefore used pulse-chase analysis to determine the fate of MHC-I.
In KBM7 US11 cells, nonconformational MHC-I is rapidly de-
graded with a half-life of ∼5 min (Fig. 2E, Upper, lanes 4–6) with
little conformational MHC-I formed (Fig. S1D, lanes 4–6). Upon
proteasome inhibition, these dislocated MHC-I molecules are vi-
sualized as faster migrating deglycosylated species (Fig. 2E, Lower,
lanes 4–6) (8), resulting from cytosolic N-glycanase removal of the
MHC I glycan (17). In KBM7 US11 TMEM129GT cells, MHC-I
degradation is prevented (Fig. 2E, lanes 7–9) and no deglycosylated
MHC-I is detected. Conformational MHC-I remains mainly EndoH-
sensitive, indicating ER residency (Fig. 2F, Lower, lanes 5–6), and
associates with a lower molecular-weight protein that comigrates
with US11 (Fig. S1D, lanes 7–9). We conclude that TMEM129 is
a novel, essential, rate-limiting protein for US11-mediated MHC-I
dislocation and degradation. In the absence of TMEM129 the ma-
jority of MHC-I are retained in the ER bound to US11, explaining
the partial rescue of cell surface MHC-I in TMEM129GT cells.
TMEM129 Is an ERAD RING E3 Ligase and Recruits Ube2J2 to Ubiquitinate
MHC-I Before US11-Induced Degradation. TMEM129 encodes an
uncharacterized 362-aa protein. Bioinformatic analysis suggests
an evolutionarily conserved, polytopic membrane protein with
three transmembrane domains and a long C-terminal tail. Al-
though lacking any yeast ortholog, TMEM129 can be traced back
to the unicellular metazoan ancestor Capsaspora owczarzaki (Fig.
3A). Exogenous TMEM129-HA colocalized with the calnexin ER
marker, consistent with ER residence (Fig. 3B). The predicted C
terminus contains conserved cysteine residues whose spacing was
reminiscent of the RING family of E3 ligases (Fig. 3A). In the
classic RING (RING-CH), cysteine and histidine residues co-
ordinate the binding of two zinc atoms, which together form the
cross-brace structural motif of the RING and stabilizes the hy-
drophobic E2 binding site (5). The RING-CH arranges these
zinc-binding residues in a C3HC4 conformation, whereas in the
Fig. 1. A haploid genetic screen identifies TMEM129 as an essential component for US11-mediated MHC-I degradation. (A) Schematic overview of genetic
screen. (B) Selection of mutant MHC-Ihigh cells by FACS. KBM7 US11 cells were mutagenised with gene-trap retrovirus and rare HLA-A2high CFPhigh cells se-
lected by two sequential rounds of FACS, with sorting gates indicated. (C) Sequencing of retroviral insertion sites in the selected HLA-A2low CFPhigh population
revealed 40 independent insertions in the TMEM129 gene on chromosome 4. The majority of gene-trap insertions cluster around the TMEM129 start site
(5′ UTR, exon 1, intron 1).
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RING-H2 variant the sequence is C3H2C3. The putative RING
of TMEM129 is unusual because it contains only cysteine, and no
histidine residues for zinc coordination, and has additional ex-
tended loops between its zinc-coordinating cysteines (AA289-308
and AA323-345). This potential TMEM129 RING also contains
a canonical E2 binding site, with an isoleucine residue between the
first two cysteines, a tryptophan in position 4 of the second loop and
a proline between the final two cysteine residues (Fig. 3A) (5).
The presence of this “cysteine-only” RING domain suggested
TMEM129 is an E3 ligase. We therefore tested whether the
TMEM129 C terminus contains a functional ubiquitin RING
with autoubiquitylation E3 ligase activity. GST fusion con-
structs of the minimal RING (TMEM129 RING) or the whole
TMEM129 C terminus (soluble TMEM129) were purified (Fig.
S2). Incubation with the E2 ubiquitin conjugase (UbcH5) and E1
activating enzyme showed robust autoubiquitination of both the
soluble and “RING-only” TMEM129 (Fig. 3C, lanes 2 and 4).
Mutation of the zinc-coordinating cysteine residues abolished
autoubiquitination in both constructs (Fig. 3C, Δcys lanes 3 and 5).
Because TMEM129 shows E3 ligase activity in vitro, we tested
whether it is indeed the cellular E3 ligase appropriated by US11
for MHC-I degradation. We initially determined whether an
active RING was required for its in vivo activity. Reconstitution
of TMEM129GT cells with wild-type TMEM129-HA, but not the
mutant RING (Δcys TMEM129-HA), restored US11-mediated
MHC-I cell surface down-regulation (Fig. 3D) and degradation
(Fig. 3E, Left). Because of MHC-I degradation, we could not
identify MHC-I bound to wild-type TMEM129, but took ad-
vantage of the catalytically inactive mutant (Δcys TMEM129)
and showed that in the presence of US11 it bound MHC-I (Fig.
3E). Lower expression of wild-type vs. Δcys TMEM129 (Fig. 3E,
Left, lanes 2 and 3) is because of toxicity of wild-type reex-
pression in gene-trap cells.
To show that TMEM129 was required for US11-mediated
MHC-I ubiquitination we initially immunoprecipitated MHC-I
and found the robust MHC-I ubiquitination induced by US11
(Fig. 3F, lane 2) was abrogated in the TMEM129GT cells (Fig. 3F,
lane 3). To confirm TMEM129 ubiquitination occurs in other cells
and that ubiquitination is specific to the MHC-I heavy chain, we
repeated the experiment in TMEM129-depleted HeLa US11 cells.
Using more stringent, denaturing conditions, we showed that MHC-
I ubiquitin species were still detected (Fig. S3A, lanes 1–3) and
disappeared upon TMEM129 depletion, suggesting TMEM129
is the ligase recruited by US11 for MHC-I ubiquitination.
As TMEM129 has an atypical RING-C2 domain, and US11-
induced MHC-I ubiquitination is not lysine-dependent (18, 19),
we screened a custom siRNA library targeting the 39 annotated
E2 conjugating enzymes for the E2 used by TMEM129 (10).
Only the ER-membrane tail-anchored E2 ubiquitin conjugase
Ube2J2 gave a significant rescue in fluorescence signal (Fig. S3B)
(z-score 5.48). We confirmed that siRNA-mediated depletion
of Ube2J2, but not Ube2J1, rescued endogenous MHC-1 in
HeLa US11 cells (Fig. 3G) and abolished US11-induced MHC-I
ubiquitination (Fig. 3H, Upper), with effective Ube2J1/2 depletions
confirmed (Fig. S3C). Therefore, the RING-C2 E3 ligase TMEM129
recruits Ube2J2 for the US11-induced MHC-I ubiquitination that
drives ER dislocation and proteasomal degradation.
US11 Associates with TMEM129 via the Rhomboid Pseudoprotease
Derlin-1. Derlin-1 is a component of the US11 retrotranslocation
complex (11, 12) and immunoprecipitation of both US11 (Fig. 4A,
Center) and Derlin-1 (Fig. 4A, Right) showed that TMEM129 is also
a member of this complex. The TMEM129–US11 interaction is de-
pendent on a polar glutamine residue in the US11 transmembrane
(Q192) (Fig. S4) as reported for the US11–Derlin-1 interaction
(12). TMEM129 binding to Derlin-1 is US11-independent (Fig. 4A,
Right), suggesting TMEM129 forms part of an endogenous Derlin-
1–containing ERAD complex. Conversely, the interaction between
Derlin-1 and US11 is independent of TMEM129 (Fig. 4A, Right).
A functional role for Derlin-1 in US11-mediated degradation
was previously shown using a dominant-negative Derlin-1–GFP
construct (12). Because Derlin-1 siRNA depletion failed to in-
hibit US11 activity, we generated Derlin-1–deficient HeLa US11
cells using CRISPR (clustered regulatory interspaced short pal-
indromic repeats) technology. Derlin-1 and TMEM129 knockout
clones from independent sgRNAs showed full MHC-I restora-
tion (Fig. 4 B and C, Left). Furthermore, whereas TMEM129
immunoprecipitated US11 in Derlin-1–sufficient cells, this in-
teraction is lost in Derlin-1–deficient cells (Fig. 4C, Right). The
TMEM129 E3 ligase is therefore recruited to US11 via Derlin-1.
US11 Avoids TMEM129-Mediated Degradation and Is Regulated by the
HRD1/SEL1L Complex. US11 levels are consistently elevated upon
TMEM129 and Ube2J2 depletion in cell models as well as in
Fig. 2. TMEM129 is essential and rate-limiting for US11-mediated MHC-I
dislocation. (A–D) Characterization of a TMEM129 gene-trapped (US11+
TMEM129GT) KBM7 clone. (A and B) MHC-I is restored in US11 TMEM129GT
cells. Control, US11, and US11 TMEM129GT KBM7 cells were examined by
RT-PCR (Upper), immunoblot (TMEM129-specific mAb) (Lower) or (B) immuno-
blotted for MHC-I (HC10), US11, or calreticulin. (C) TMEM129 rescues the
US11 phenotype in US11 TMEM129GT cells. Cytofluorometric analysis of HLA-A2
and HLA-B in TMEM129GT (red), US11 (green), and control (black) KBM7 cells
(panels 1 and 3) and complemented with HA-tagged TMEM129 (panels 2
and 4). (D) TMEM129 is required for the US11-induced MHC-I down-regu-
lation in HCMV-infected cells. Human foreskin fibroblast primary fibroblasts
were stably transduced with control or TMEM129-specific shRNA, then infec-
ted with HCMV TB40Bac4 (multiplicity of infection, MOI 25) or UV-inactivated
virus and after 48 h lysates immunoblotted for HLA-A2 (HCA2), US11,
TMEM129, HCMV immediate early protein (IE1/2), or calreticulin. (E) US11
TMEM129GT cells do not dislocate or degrade MHC-I. Control, US11, and
US11 TMEM129GT KBM7 cells were [35S]methionine pulse-labeled for 10 min,
and MHC-I HC immunoprecipitated from lysates at the indicated times in the
absence (Upper) or presence (Lower) of the MG132 proteasome inhibitor. (F)
US11 TMEM129GT cells retain MHC-I in the ER in a partially folded state.
KBM7, KBM7 US11, and KBM7 US11 TMEM129GT cells were immunopreci-
pitated with nonconformational (HC10, Upper) or conformational (W6/32,
Lower), incubated ± EndoH, and immunoblotted for MHC-1 (HC10).
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HCMV infection (Figs. 2 B and D, 4 A and C, and 5A), suggesting
US11 might also be degraded in a TMEM129 pathway. However,
the 1-h half-life of US11 (Fig. S5A) is much longer than the very
short half-life of MHC I (<5 min) (Fig. 2E), arguing against
codegradation in a TMEM129-dependent pathway. We there-
fore asked whether the increase in steady-state US11 following
TMEM129 depletion was indirect (i.e., secondary to the in-
creased MHC-I levels that, following TMEM129 depletion, ac-
cumulate in the ER bound to US11) (Fig. S1D, lanes 7–9). To
test this hypothesis, we examined whether soluble HLA-A2,
which is not a substrate of US11 (Fig. 5B, lanes 5 and 6), affected
US11 levels and activity. A GFP-tagged soluble HLA-A2 in-
creased US11 levels (Fig. 5B, lane 5), which still retained activity
against endogenous MHC-I (Fig. 5B, lane 5). Under these con-
ditions, TMEM129 depletion did not further increase US11 levels
(Fig. 5B, lanes 5 and 6). It therefore seems unlikely that a sig-
nificant fraction of US11 is degraded by TMEM129. Instead,
US11 stability seems dependent on stable binding to its MHC-I
client. Consistent with this notion, the time course of US11 deg-
radation is more reminiscent of the cellular degradation of en-
dogenous misfolded proteins (20). We therefore asked whether
US11 is targeted by known components of the cellular quality-
control machinery. We found that depletion of HRD1, and its lu-
minal substrate recruitment factor SEL1L, but not Gp78, stabilized
Fig. 3. TMEM129 is an ER resident E3 ubiquitin ligase that with Ube2J2
ubiquitinates MHC-I before US11-induced dislocation. (A) Schematic of
TMEM129, with the indicated RING domain alignments. Zinc-coordinating
cysteine (red), histidine (blue), and conserved residues of the E2 binding site
(green) are indicated. (HsTMEM129, Homo sapiens; CoTMEM129, C. owczarzaki).
(B) TMEM129-HA colocalizes with the ER marker calnexin. HeLa cells were
transfected with TMEM129-HA, fixed, and immunostained for TMEM129-HA
(HA, red), calnexin (ER, green), and TGN46 (Golgi, blue). (Magnification:
64×.) (C) The TMEM129 RING shows in vitro E3 ligase activity. GST-tagged
wild-type or Δcys RING TMEM129 or soluble TMEM129 was purified and
incubated in an in vitro ubiquitination reaction with UbcH5, E1, ubiquitin,
and ATP. Immunoblots were analyzed for ubiquitin (P4D1), TMEM129, and
GST. (D) Wild-type but not RING-mutant (Δcys) TMEM129-HA restores HLA-
A2 down-regulation in US11+ TMEM129GT cells. Cytofluorometric analysis
of HLA-A2 in US11+ TMEM129GT cells expressing wild-type or Δcys
TMEM129-HA upstream of an IRES mCherry. (E) Catalytically inactive
TMEM129 binds its MHC-I substrate. mCherry+ cells from expressing vector,
wild-type or Δcys TMEM129-HA were isolated by FACS and directly immuno-
blotted (Left), or following HA-tag immunoprecipitations, eluted proteins
probed for MHC-I and HA (Right). (F) TMEM129 is required for US11-induced
MHC-I ubiquitination. MHC-I (HC10) was immunoprecipitated from 1% Triton
X-100 lysates of MG132-treated KBM7, KBM7 US11, and KBM7 US11
TMEM129GT cells and immunoblotted for ubiquitin (VU-1) or MHC-I (HC10).
(G and H) The E2 Ube2J2 is essential for US11-induced MHC-I ubiquitination
and degradation. (G) Cytofluorometric analysis of GFP–HLA-A2 in HeLa GFP–
HLA-A2 US11 cells depleted of Ube2J1 or Ube2J2. (H) MHC-I ubiquitination
was assessed as in F on Ube2J2 or mock-depleted HeLa US11 cells.
Fig. 4. The rhomboid pseudoprotease Derlin-1 recruits US11 to TMEM129.
(A) TMEM129 is recruited to a Derlin-1–US11 complex. KBM7, KBM7 US11,
and KBM7 US11 TMEM129GT cells were lysed in 1% digitonin, immunopre-
cipitated with US11 (Center) or Derlin-1 (Right) antisera and probed for
endogenous TMEM129, Derlin-1, or US11. (B) CRISPR-Cas9 knockout clones
of Derlin-1 and TMEM129 restore cell surface HLA-B in US11-expressing cells.
Cytofluorometric analysis of cell surface HLA-B on HeLa GFP-HLA-A2.US11
clones targeted with two independent short guide RNAs (sg) for Derlin-1 or
TMEM129. (C) Derlin-1 bridges US11 to TMEM129. Endogenous TMEM129
was immunoprecipitated from CRISPR Cas9 generated TMEM129 knockout
(TMEM129 sg1/2) or Derlin-1 knockout (Derlin-1 sg1/2) HeLa US11 clones and
eluted proteins probed for US11, Derlin-1, and TMEM129 (Right). Immuno-
blotting of whole-cell lysates is shown (Left).
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US11 (Fig. 5C) without affecting MHC-I levels. We conclude
that US11 is regulated by substrate availability and is itself degraded
by the HRD1/SEL1L complex. Therefore, although US11 is tar-
geted for slow HRD1-mediated degradation by the ER quality-
control machinery, the MHC-I–US11 complex triggers rapid rec-
ognition and MHC-I dislocation via TMEM129.
US11 Tagged with a MHC-I Cytosolic Tail Is Rapidly Degraded by
TMEM129 and Unable to Catalyze MHC-I Degradation. How does
US11 catalyze MHC-I degradation by TMEM129 while escaping
rapid degradation itself? Although the luminal domain of US11
binds MHC-I, and its transmembrane domain recruits the dis-
location machinery (21), the cytosolic tail of US11 is dispensable
for its activity. In contrast, degradation by US11 requires the cyto-
solic tail of MHC-I, which is the most likely site of TMEM129-
mediated ubiquitination (22). MHC-I’s tail contains multiple
potential ubiquitin acceptor sites (Fig. 5D), whereas the cyto-
plasmic tail of US11 is short and devoid of ubiquitination sites,
with a membrane proximal lysine residue buried just beyond the
transmembrane domain and a single exposed serine residue (Fig.
5D). We therefore asked whether replacing the cytosolic tail of
US11 with the tail of HLA-A2 (US11-A2tail) might target US11 for
rapid, TMEM129-mediated degradation. Strikingly, the US11-A2tail
is rapidly degraded in a TMEM129-dependent pathway (Fig. 5E),
with its half-life decreasing to ∼8 min (US11-A2tail) (Fig. 5F),
comparable to the half-life of US11-degraded MHC-I. These
data imply that the tail of HLA-A2, but not US11, constitutes
a substrate for rapid TMEM129-mediated degradation. Addi-
tional functional consequences of the HLA-A2 tail swap with
US11 were also striking. Whereas endogenous MHC-I is rapidly
degraded by wild-type US11 or US11Δtail mutant (23), in the
presence of US11-A2tail, MHC-I remains stable and is no longer
degraded (Fig. 5E), even though US11-A2tail shows MHC-I binding
(Fig. S5B). Therefore, the US11-A2tail fusion becomes the preferred
TMEM129 substrate, and endogenous MHC-I is ignored.
Discussion
US11 is one of HCMV’s most potent immune modulators and
herein we have shown that TMEM129 is a novel membrane-bound
RING E3 ligase that, together with its cognate E2 UbE2J2, is
both essential and rate-limiting for US11-mediated degradation
of MHC-1. By uncoupling US11 from the dislocation machinery
we show that US11 retains its substrate in the ER, a common
mechanism used by many viral proteins to prevent substrate ex-
pression. Linking up with the TMEM129 cellular E3 ligase pro-
vides a very efficient way to down-regulate MHC-I, which cannot
be overcome by increased MHC-1 expression. US11’s cytosolic
tail protects it from rapid degradation by TMEM129, and US11 is
instead turned over by the HRD1/SEL1L ligase complex.
The TMEM129 RING domain is unusual in containing only
cysteine residues for zinc coordination and extended loops.
“Cysteine-only” RINGs, previously referred to as RING-C2 do-
mains, are rare and difficult to predict because of their resemblance
to other zinc-finger motifs. cNOT4 is the only human E3 ligase
with a characterized RING-C2 (24), and other cysteine-only
ligases might remain unidentified. A PROSITE search identified
RING-C2 domains in the family of RFPL proteins and the RBR
ligases HOIP (RING1) and RNF216 (RING2). Because the
TMEM129 RING shows closer homology to RING-HC domains
than cNOT4, we suggest that TMEM129 originated from a clas-
sic RING E3 ligase rather than being part of a larger RING-C2
ligase family. Despite the lack of TMEM129-related mammalian
proteins, TMEM129 and its unusual RING-C2 domain are con-
served throughout holozoa, including the unicellular C. owczarzaki,
implying an important and conserved cellular function.
Although TMEM129 depletion stabilized US11 as well as MHC-I,
our initial assumption that US11 and MHC-I were codegraded
by the TMEM129 E3 ligase was inconsistent with the very dif-
ferent half-life of the proteins. The stabilization of US11 upon
TMEM129 depletion was mimicked by exogenous expression of
a soluble, US11-insensitive MHC-I, suggesting that US11 is stabi-
lized by direct binding to its client MHC-I protein. In the absence of
MHC-I, US11 is degraded in a TMEM129-independent pathway,
presumably via a degron overlapping with the MHC-I binding site.
Consistent with this result we found US11 degradation to be
dependent on the HRD1 E3 ligase and its luminal substrate re-
cruitment factor SEL1L.
We therefore suggest HCMV US11 engages two degradation
pathways: a Derlin-1/TMEM129/Ube2J2-dependent pathway in-
volved in the degradation of MHC-I and a SEL1L/HRD1-depen-
dent pathway involved in the degradation of “free” US11. The
TMEM129 pathway is prevented from ubiquitinating US11 by
a short cytosolic tail with few ubiquitination sites. HRD1 does not
ubiquitinate US11-associated MHC-I, even though disassembled
MHC-I is a potent HRD1 client (20). Remarkably, a tail swap
between US11 and MHC-I allowed US11 to be rapidly degraded in
a TMEM129-dependent manner, leaving endogenous MHC-I un-
touched. Clearly a separation between both pathways is essential for
US11 function, achieved by deflecting TMEM129’s ubiquitination
onto the MHC-I tail with US11 acting as a pseudosubstrate. Both
pathways are, however, intimately linked because TMEM129 de-
pletion rescues MHC-I, which in turn stabilizes US11. Conversely
HRD1/SEL1L-mediated degradation of free US11 might enhance
TMEM129-mediated degradation of MHC-I by limiting the number
Fig. 5. US11 is stabilized by its MHC-I substrate but escapes degradation by
TMEM129. (A) US11 is stabilized by TMEM129 or Ube2J2 depletion. HeLa
US11 cells were siRNA-depleted of TMEM129 (96 h) or Ube2J2 (72 h) and
immunoblots probed for US11 and MHC-I. (B) Soluble HLA-A2 rescues US11
expression. TMEM129 was siRNA depleted from HeLa US11 cells expressing
GFP, GFP–HLA-A2, or GFP-soluble HLA-A2, and lysates probed for US11, GFP
(HLA-A2), MHC-I (HC10), and TMEM129. (C) US11 is degraded via a HRD1/SEL1L
pathway. HeLa US11 cells were siRNA depleted of TMEM129, HRD1, SEL1L, or
Gp78 and lysates probed for US11, MHC-I, TMEM129, HRD1, and SEL1L. (D)
Schematic of HLA-A2 and US11 cytosolic tail. Putative ubiquitination sites are
shown in bold. (E and F) Transfer of the HLA-A2 cytosolic tail to US11 induces its
rapid TMEM129-dependent degradation, leaving MHC-I unaffected. TMEM129
was siRNA-depleted from HeLa cells expressing HA-US11 or HA-US11-A2tail. Cells
were (E) probed by immunoblot for HA, MHC-I (HC10), or TMEM129 or (F) [35S]
methionine pulse-labeled and analyzed by autoradiography following HA-tag
immunoprecipitations at the indicated time points.
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of US11 molecule TMEM129 screens to find a US11 loaded with
MHC-I. Such a flexible degradation system based on stabiliza-
tion of the degradation machinery by a client protein, might al-
low US11 expression to rapidly adapt to changes in MHC-I ex-
pression, as might occur under the influence of IFN or other viral
immune modulators.
TMEM129’s strong interaction with Derlin-1 and the Derlin-1
knockout confirmed the central role of this protein in US11
activity. Derlin-1 bridges US11 to TMEM129 but interacts with
other ERAD E3 ligases, including HRD1, Gp78, and RMA-1,
making it surprising that TMEM129 is the sole ligase able to
catalyze US11-induced protein dislocation. Other ERAD E3
ligases cannot substitute for TMEM129, as depletions of neither
Hrd1/Gp78 (Fig. 5C) nor TRC8 (Fig. S1C) prevented MHC-I
degradation, implying that TMEM129 is the sole ligase re-
sponsible for US11-mediated MHC-I degradation. We therefore
predict that TMEM129 plays an important role in the ubiquiti-
nation and degradation of Derlin-1–specific protein substrates.
Derlin-1’s role within the US11 system is difficult to study be-
cause Derlin-1 depletion dissociates viral US11 from TMEM129,
disrupting ubiquitination, recognition, and dislocation. If Derlin-1
is part of the retrotranslocon (25, 26), US11 binding might directly
impact on channel opening and substrate dislocation.
The role of ubiquitin in US11-induced protein dislocation has
been difficult to establish, not least because US11 is able to de-
grade a “lysine-less” MHC-I heavy chain (19). Ubiquitin can be
conjugated to nonlysine residues, including serine, threonine, or
cysteine residues and the protein N terminus (27, 28). TMEM129-
dependent ubiquitination of MHC-I might proceed on a combi-
nation of lysine and nonlysine residues, consistent with the iden-
tification of Ube2J2 as TMEM129’s cognate E2. Ube2J2 is also
recruited by the MHVγ68 mK3 viral E3 ligase for ubiquitination
of MHC-I on nonlysine residues (28).
Paradoxically, it is US11’s potent ability to reduce MHC-I
levels and alter antigen presentation that recently attracted at-
tention in HIV vaccination studies. Simian Immunodeficiency
Virus (SIV) vaccination, in the context of rhesus CMV (RhCMV),
gives a unique long-term protection against subsequent SIV in-
fection, that is exclusively dependent on the RhCMV US11 ho-
molog (Rh189) (29). SIV normally evades immune recognition by
mutation of its dominant antigens (30). US11 likely suppresses the
dominant canonical T-cell response, allowing immune detection of
protective SIV epitopes. Our characterization of TMEM129 as
a novel E3 ligase and the rate-limiting component of HCMVUS11-
induced protein dislocation, therefore not only uncovers a novel
mammalian ERAD pathway, but might aid in future targeting of
viral diseases and vaccine design.
Materials and Methods
Details of experimental procedures, constructs, and reagents can be found in
SI Materials and Methods.
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